NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering"). The gross proceeds to Eyenovia from this Offering are approximately $5.14 million, before deducting the placement agent's fees and other offering expenses payable by Eyenovia. Eyenovia intends to use the net proceeds from this Offer ...

Eyenovia Inc EYEN stock is trading higher on Thursday after its plunge yesterday, with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro. On Wednesday, the ophthalmic technology company agreed to sell 12.85 million shares at $0.40 per share. The aggregate gross proceeds to the company from the offering are expected to be approximately $5.14 million. The company will use the net proceeds to fund commercialization activities for its products, Mydcombi and clobetas ...

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering"). The closing of the Offering is expected to occur on or about August 22, 2024, subject to the satisfaction of customary closing conditions. All of the securities in the Offering are being sold by Eyenovia. Dawson James Securities, Inc. is actin ...

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof) in a best efforts offering. All of the securities to be sold in the offering are to be offered by Eyenovia. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the ...

Eyenovia, Inc. (EYEN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a changing ea ...

Core Viewpoint - Eyenovia, Inc. reported a quarterly loss of $0.18 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.17, indicating a negative earnings surprise of -5.88% [1] Financial Performance - The company posted revenues of $0.02 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 98.33%, compared to zero revenues a year ago [2] - Over the last four quarters, Eyenovia has surpassed consensus EPS estimates only once [2] Stock Performance - Eyenovia shares have declined approximately 58.7% since the beginning of the year, contrasting with the S&P 500's gain of 12% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $1.6 million, and for the current fiscal year, it is -$0.76 on revenues of $5.03 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Eyenovia belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Eyenovia's stock performance [5]

Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for analysis in Q4 Commenced sales activities with focus on Mydcombi in 260+ offices and preparations for launch of clobetasol propionate ophthalmic suspension 0.05%, the first new ophthalmic steroid to enter the market in 15 years Announced developme ...

Core Insights - Eyenovia, Inc. has signed a non-binding agreement with Formosa Pharmaceuticals to co-develop a formulation of clobetasol propionate ophthalmic suspension 0.05% for the short-term relief of dry eye disease [1][2] - The collaboration aims to share development costs and profits upon commercialization, expanding an existing partnership that began in February 2023 [2] - Clobetasol propionate was approved by the FDA on March 4, 2024, for reducing inflammation and pain associated with approximately seven million ocular surgeries performed annually in the U.S. [3] Company Overview - Eyenovia, Inc. is a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia [1] - The company is also developing the Optejet device for use with its drug-device therapeutic products [5] - Eyenovia's current product lineup includes Mydcombi™ and clobetasol propionate ophthalmic suspension [5] Market Potential - The U.S. market for topical ocular steroids and steroid combinations is approximately $1.3 billion [3] - The new indication for clobetasol propionate could significantly increase its usage among millions of dry eye patients experiencing flare-ups [3] - Formosa's proprietary APNT® nanoparticle formulation platform enhances the bioavailability of clobetasol propionate, potentially improving treatment outcomes [4]

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercialstage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that it has signed a non-binding agreement with Taiwan-based Formosa Pharmaceuticals (TWO:6838) whereby the companies will co-develop a formulation of clobetasol propionate ophthalmic suspension 0.05% ("clobetasol propionate") in combination with the Optejet device for the shortterm relief of dry ...

Eyenovia, Inc. is an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis, Clobetasol Propionate Ophthalmic Suspension, 0.05% for postsurgical inflammation and pain, and developing the Optejet® device for use both in connection with its own drug-device therapeutic product for pediatric progressive myopia as well as outlicensing for additional indications. For more information, please visit Eyenovia.com. Except for histor ...